Velaglucerase alfa

Velaglucerase alfa
Clinical data
Trade names	Vpriv
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Velaglucerase alfa;
Routes of; administration	Intravenous
ATC code	A16AB10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	Plasma: 5–12 minutes (absorbed by macrophages)
Identifiers
CAS Number	884604-91-5 ;
DrugBank	DB06720 ;
ChemSpider	none;
UNII	23HYE36B0I;
KEGG	D09029;
ChEMBL	ChEMBL1201865 ;
Chemical and physical data
Formula	C2532H3850N672O711S16
Molar mass	55593.61 g·mol−1
	(what is this?) (verify)

Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.^[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.^[2] It is manufactured by Shire plc.

The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.^[3]

Velaglucerase alfa was approved for medical use in the United States in February 2010,^[4]^[5] and in the European Union in August 2010.^[3]

Medical uses

Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.^[3]^[1]

References

^ ^a ^b ^c "Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution". DailyMed. 18 June 2020. Archived from the original on 24 March 2021. Retrieved 13 August 2020.
^ Burrow TA, Grabowski GA (February 2011). "Velaglucerase alfa in the treatment of Gaucher disease type 1". Clinical Investigation. 1 (2): 285–293. doi:10.4155/cli.10.21. PMC 3172711. PMID 21927713.
^ ^a ^b ^c "Vpriv EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 October 2020. Retrieved 13 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease". Medical News Today. 27 February 2010. Archived from the original on 13 June 2011. Retrieved 6 March 2010.
^ "Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575". U.S. Food and Drug Administration (FDA). 24 February 2010. Archived from the original on 3 April 2021. Retrieved 17 February 2023.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Velaglucerase_alfa
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[Vpriv_FDA_label-1] "Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution". DailyMed. 18 June 2020. Archived from the original on 24 March 2021. Retrieved 13 August 2020.

[pmid21927713-2] Burrow TA, Grabowski GA (February 2011). "Velaglucerase alfa in the treatment of Gaucher disease type 1". Clinical Investigation. 1 (2): 285–293. doi:10.4155/cli.10.21. PMC 3172711. PMID 21927713.

[Vpriv_EPAR-3] "Vpriv EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 October 2020. Retrieved 13 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease". Medical News Today. 27 February 2010. Archived from the original on 13 June 2011. Retrieved 6 March 2010.

[5] "Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575". U.S. Food and Drug Administration (FDA). 24 February 2010. Archived from the original on 3 April 2021. Retrieved 17 February 2023.

[1]

[2]

[3]

[4]

[5]

v t e Other alimentary tract and metabolism products (A16)
Amino acids and derivatives	Ademetionine Betaine Carglumic acid Glutamine Levocarnitine Mercaptamine Metreleptin
Enzymes	Amino acids: phenylalanine ammonia-lyase (Pegvaliase) Carbohydrate metabolism: sucrase (Sacrosidase) alpha-glucosidase (Alglucosidase alfa, Avalglucosidase alfa, Cipaglucosidase alfa) Glycolipid/sphingolipid: glucocerebrosidase (Alglucerase Imiglucerase Taliglucerase alfa Velaglucerase alfa) alpha-galactosidase (Agalsidase alfa Agalsidase beta Pegunigalsidase alfa) Glycosaminoglycan: iduronidase (Laronidase) arylsulfatase B (Galsulfase) iduronate-2-sulfatase (Idursulfase) idursulfase beta Lipid: lysosomal lipase (Sebelipase alfa) Phosphate: Asfotase alfa atidarsagene autotemcel cerliponase alfa eladocagene exuparvovec elosulfase alfa olipudase alfa pabinafusp alfa pegzilarginase vestronidase alfa
Other	Anethole trithione Eliglustat Givosiran Glycerol phenylbutyrate Leriglitazone Lumasiran Miglustat Nedosiran Nitisinone Sapropterin Sodium benzoate (+sodium phenylacetate) Sodium phenylbutyrate Teduglutide Trientine Tioctic acid Triheptanoin Uridine triacetate Velmanase alfa Zinc acetate